Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1LG | ISIN: IL0011224156 | Ticker-Symbol:
NASDAQ
27.06.25 | 18:26
1,000 US-Dollar
-1,96 % -0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ICECURE MEDICAL LTD Chart 1 Jahr
5-Tage-Chart
ICECURE MEDICAL LTD 5-Tage-Chart

Aktuelle News zur ICECURE MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiIceCure Medical Ltd. - 6-K, Report of foreign issuer-
MiIceCure Medical Ltd. - F-1/A, Registration statement for certain foreign private issuers1
16.06.IceCure Medical Ltd. - F-1, Registration statement for certain foreign private issuers3
09.06.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
09.06.IceCure Medical: IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes97IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer ...
► Artikel lesen
30.05.H.C. Wainwright maintains Buy on IceCure Medical, target at $2.501
29.05.IceCure Medical GAAP EPS of -$0.06 beats by $0.01, revenue of $0.73M misses by $0.25M2
28.05.IceCure Medical Ltd Q1 Loss Decreases, Beats Estimates-
ICECURE MEDICAL Aktie jetzt für 0€ handeln
28.05.IceCure Medical GAAP EPS of -$0.06 beats by $0.02, revenue of $0.73M misses by $0.02M3
28.05.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
28.05.IceCure Medical Reports First Quarter 2025 Financial Results98Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage...
► Artikel lesen
27.05.Earnings Preview For Icecure Medical1
21.05.IceCure Medical Ltd. - 6-K, Report of foreign issuer2
30.04.IceCure Medical Ltd. - 6-K, Report of foreign issuer-
30.04.IceCure Medical: IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense Cryoablation in Women 70+ with Early-Stage Breast Cancer82Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage...
► Artikel lesen
10.04.IceCure Medical Ltd. - 6-K, Report of foreign issuer2
28.03.IceCure Medical Stock Dips Despite Positive ICESECRET Study Results1
28.03.IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript1
28.03.H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target1
27.03.IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense Cryoablation Sales in North America468Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through...
► Artikel lesen
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1